[1]董宇梁 周帆 迟立群 穆军升.卡格列净对心脏外科手术关联的心功能不全改善作用的研究进展[J].心血管病学进展,2025,(9):778.[doi:10.16806/j.cnki.issn.1004-3934.2025.00.003]
　DONG Yuliang,ZHOU Fan,CHI Liqun,et al.Improvement Effects of Canagliflozin on Cardiac Insufficiency Associated with Cardiac Surgery[J].Advances in Cardiovascular Diseases,2025,(9):778.[doi:10.16806/j.cnki.issn.1004-3934.2025.00.003]
点击复制

卡格列净对心脏外科手术关联的心功能不全改善作用的研究进展()

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2025年9期
页码:
778
栏目:
综述
出版日期:
2025-09-25

文章信息/Info

Title:
Improvement Effects of Canagliflozin on Cardiac Insufficiency Associated with Cardiac Surgery
作者:
董宇梁1 周帆 2 迟立群3 穆军升3; 4
(1.首都医科大学,北京 100069;2.解放军总医院第三医学中心超声科,北京 100039;3.首都医科大学附属北京安贞医院 北京市心肺血管疾病研究所心脏外科,北京 100029;4.新乡医学院第三附属医院心脏外科,河南 新乡 453000)
Author(s):
DONG Yuliang1; ZHOU Fan 2; CHI Liqun3; MU Junsheng 3; 4
?1.Capital Medical University,Beijing 100069,China; 2. Department of Ultrasound,The Third Medical Center of Peoples Liberation Army of China General Hospital,Beijing 100039,China ; 3.Department of Cardiac Surgery,Beijing Anzhen Hospital,Capital Medical University,Beijing Institute of Heart Lung and Blood Vessel Diseases,Beijing 100029,China; 4.Department of Cardiac Surgery,The Third Affili ated Hospital of Xinxiang Medical University,Xinxiang 453000,Henan,China)?/html>
关键词:
卡格列净; 心功能不全; 心脏外科手术; 钠-葡萄糖共转运蛋白-2抑制剂
Keywords:
Canagliflozin;  Cardiac insufficiency; Cardiac surgery; Sodium-glucose co-transporter 2 inhibitor
DOI:
10.16806/j.cnki.issn.1004-3934.2025.00.003
摘要:
本综述梳理了卡格列净在改善心脏外科手术相关心功能不全方面的研究进展。多项动物与临床研究结果显示，卡格列净可通过调节代谢、改善血流动力学、抑制炎症及纤维化等多途径机制缓解心力衰竭症状，降低不良心血管事件风险。尽管现有研究样本量较小、随访时间有限，初步证据已提示其在术后心力衰竭管理中的潜力。未来需开展更大规模、长期随访的临床试验，明确其疗效、安全性及围手术期用药策略，以指导个体化治疗。
Abstract:
This review summarizes current findings on the role of canagliflozin in improving cardiac insufficiency associated with cardiac surgery . Multiple animal and clinical studies have shown that canagliflozin can alleviate heart failure symptoms and reduce the risk of adverse cardiovascular events through multiple mechanisms such as regulating metabolism,improving hemodynamics,inhibiting inflammation and fibrosis. Despite limitations in sample size and follow-up duration,preliminary data support its therapeutic potential in postoperative care. In the future,larger scale and long-term follow-up clinical trials are needed to clarify their efficacy,safety and perioperative medication strategies,in order to guide individualized treatment

参考文献/References:

[1] Schwann AN,Jaffe LM,Givertz MM,et al. Early initiation of guideline-directed medical therapy for heart failure after cardiac surgery[J]. Ann Thorac Surg,2024,118(4):792-800.

[2] McDonagh TA,Metra M,Adamo M,et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Eur Heart J,2021,42(36):3599-3726.

[3] Paparella D,Yau TM,Young E. Cardiopulmonary bypass induced inflammation:pathophysiology and treatment. An update[J]. Eur J Cardiothorac Surg,2002,21(2):232-244.

[4] van der Pol A,van Gilst WH,Voors AA,et al. Treating oxidative stress in heart failure:past,present and future[J]. Eur J Heart Fail,2019,21(4):425-435.

[5] Hausenloy DJ,Yellon DM. Myocardial ischemia-reperfusion injury:a neglected therapeutic target[J]. J Clin Investig,2013,123(1):92-100.

[6] Jiang H,Fang T,Cheng Z. Mechanism of heart failure after myocardial infarction[J]. J Int Med Res,2023,51(10):3000605231202573.

[7] Neal B,Perkovic V,Mahaffey KW,et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes[J]. N Engl J Med,2017,377(7):644-657.

[8] Spertus JA,Birmingham MC,Nassif M,et al. The SGLT2 inhibitor canagliflozin in heart failure:the CHIEF-HF remote,patient-centered randomized trial[J]. Nat Med,2022,28(4):809-813.

[9] Vaduganathan M,Docherty KF,Claggett BL,et al. SGLT-2 inhibitors in patients with heart failure:a comprehensive meta-analysis of five randomised controlled trials[J]. Lancet,2022,400(10354):757-767.

[10] McGuire DK,Shih WJ,Cosentino F,et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis[J]. JAMA Cardiol,2020,6(2):1.

[11] Yh T,Yn T,Nl S,et al. Effects of sodium/glucose cotransporter 2(SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials[J]. J Am Heart Assoc,2021,10(5):e019463.

[12] Kutoh E,Hayashi J. Effect of canagliflozin on heart function involving ketone bodies in patients with type 2 diabetes[J]. Drug Res(Stuttg),2019,69(5):297-300.

[13] Harris DD,Sabe SA,Xu CM,et al. Sodium-glucose co-transporter 2 inhibitor canagliflozin modulates myocardial metabolism and inflammation in a swine model for chronic myocardial ischemia[J]. Surgery,2024,175(2):265-270.

[14] Kawasoe S,Maruguchi Y,Kajiya S,et al. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes[J]. BMC Pharmacol Toxicol,2017,18(1):23.

[15] Woods TC,Satou R,Miyata K,et al. Canagliflozin prevents intrarenal angiotensinogen augmentation and mitigates kidney injury and hypertension in mouse model of type 2 diabetes mellitus[J]. Am J Nephrol,2019,49(4):331-342.

[16] Satou R,Cypress MW,Woods TC,et al. Blockade of sodium-glucose cotransporter 2 suppresses high glucose-induced angiotensinogen augmentation in renal proximal tubular cells[J]. Am J Physiol Renal Physiol,2020,318(1):F67-F75.

[17] Mancini SJ,Boyd D,Katwan OJ,et al. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms[J]. Sci Rep,2018,8(1):5276.

[18] Zuo Q,He L,Ma S,et al. Canagliflozin alleviates atherosclerosis progression through inflammation, oxidative stress, and autophagy in western diet-fed ApoE ?/? mice[J]. Cardiovasc Innov Appl,2024,9:981.

[19] Butler J,Hamo CE,Filippatos G,et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors[J]. Eur J Heart Fail,2017,19(11):1390-1400.

[20] Sayour AA,Korkmaz-Ic?z S,Loganathan S,et al. Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation[J]. J Transl Med,2019,17:127.

[21] Ma M,Lian S,Kraft P,et al. Sodium-glucose cotransporter-2 inhibitor canagliflozin improves vascular graft function in a rat bypass model[J]. Thorac Cardiovasc Surgeon,2025,73(S 01):S1-S71.

[22] Ma S,Zuo QJ,He LL,et al. Canagliflozin can improve cardiac function in HFpEF rats partly by regulating ferroptosis[J]. Zhonghua Xin Xue Guan Bing Za Zhi,2024,52(9):1090-1100.

[23] Sardu C,Massetti M,Testa N,et al. Effects of sodium-glucose transporter 2 inhibitors(SGLT2-I) in patients with ischemic heart disease(IHD) treated by coronary artery bypass grafting via MiECC:inflammatory burden, and clinical outcomes at 5 years of follow-up[J]. Front Pharmacol,2021,12:777083.

[24] 柳莹莹,田阳玲,王琼琳. 卡格列净对行生物瓣膜置换术的2型糖尿病老年患者的短期预后影响[J]. 中国心血管杂志,2022,27(6):552-556.

[25] 周雁花,王文博,刘红阳,等. 卡格列净对心力衰竭患者心肌能量代谢影响的临床研究[J]. 中国处方药,2024,22(10):134-137.

[26] Jain SS,Yu J,Arnott C,et al. Treatment effect of canagliflozin for patients on therapy for heart failure:pooled analysis of the CANVAS program and CREDENCE trial[J]. Int J Cardiol,2024,395:131444.

[27] Brekke HK,Holmaas G,Astor MC,et al. Metabolic acidosis in patients with diabetes 2 undergoing cardiac surgery:the impact of SGLT2 inhibitor use:a retrospective cohort study[J]. Eur J Anaesthesiol,2025,42(2):152-161.

[28] Sridharan K,Sivaramakrishnan G. Risk of diabetic ketoacidosis associated with sodium glucose cotransporter-2 inhibitors:a network meta-analysis and meta-regression[J]. J Clin Med,2024,13(6):1748.

[29] Shin H,Paik JM,Everett BM,et al. Comparative effectiveness of individual sodium-glucose cotransporter 2 inhibitors[J]. JAMA Intern Med,2025,185(3):302-313.

[30] Duvalyan A,la Hoz RM,McGuire DK,et al. Sodium-glucose cotransporter 2 inhibitors and mycotic genital or urinary tract infections in heart failure[J]. J Card Fail,2024,30(8):1031-1040.

[31] 白婷,朱琳,杨蕊,等. 基于WHO药品不良反应报告数据库的4种钠-葡萄糖共转运蛋白-2抑制剂不良反应特点分析[J]. 临床药物治疗杂志,2025,23(2):79-86.

[32] Auerbach JS,Alnajar A,Patel SS,et al. Retrospective chart review of euglycemic diabetic ketoacidosis rates and outcomes postimplementation of sodium glucose cotransporter 2 inhibitor use stoppage 5 days before open heart surgery [J]. J Cardiothorac Vasc Anesth,2025,39(6):1441-1450.

相似文献/References:

[1]王菲 卢新政.卡格列净对2型糖尿病患者心血管保护作用的研究进展[J].心血管病学进展,2020,(3):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
　WANG Fei,LU Xinzheng.Cardiovascular Protection of Canagliflozin in Type 2 Diabetes Patients[J].Advances in Cardiovascular Diseases,2020,(9):231.[doi:10.16806/j.cnki.issn.1004-3934.2020.03.004]
[2]傅文霞 乐佳玮 李若谷.完全性左束支阻滞的冠心病患者中合并心功能不全的相关危险因素分析[J].心血管病学进展,2020,(12):1310.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
　FU Wenxia,LE Jiawei,LI Ruogu.Analysis of Risk Factors for Cardiac Dysfunction in Patients with Coronary Heart Disease Complicated with Complete Left Bundle Branch Block[J].Advances in Cardiovascular Diseases,2020,(9):1310.[doi:10.16806/j.cnki.issn.1004-3934.2020.12.021]
[3]李铭,高继先,吴冰,等.卡格列净减轻心肌梗死后细胞凋亡及炎症反应改善预后[J].心血管病学进展,2024,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.018]
　LI Ming,GAO Jixian,WU Bing,et al.Canagliflozin alleviates apoptosis and inflammation after myocardial infarction, and improves prognosis[J].Advances in Cardiovascular Diseases,2024,(9):368.[doi:10.16806/j.cnki.issn.1004-3934.2024.04.018]
[4]沈鐲钰 黄丹 赵淑红 马振国.卡格列净对阿霉素所致心肌细胞损伤的作用及机制研究[J].心血管病学进展,2025,(3):272.[doi:10.16806/j.cnki.issn.1004-3934.2025.03.017]
　SHEN Zheyu,HUANG Dan,ZHAO Shuhong,et al.Canagliflozin’s Role in Ameliorating Doxorubicin-Induced Injury in Cardiomyocytes[J].Advances in Cardiovascular Diseases,2025,(9):272.[doi:10.16806/j.cnki.issn.1004-3934.2025.03.017]

更新日期/Last Update: 2025-12-18